Document is current
Any future updates will be listed below
-
Authors
Barroux, Melissa https://orcid.org/0000-0002-7682-0932
Househam, Jacob
Lakatos, Eszter https://orcid.org/0000-0002-7221-6850
Ronel, Tahel https://orcid.org/0000-0002-9513-9181
Baker, Ann-Marie https://orcid.org/0000-0001-8905-9137
Salié, Henrike https://orcid.org/0000-0002-2993-3782
Mossner, Maximilian
Smith, Kane
Kimberley, Chris
Nowinski, Salpie
Berner, Alison
Gunasri, Vinaya
Borgmann, Martin https://orcid.org/0000-0002-8195-2796
Liffers, Sven
Jansen, Marnix https://orcid.org/0000-0003-0645-564X
Caravagna, Giulio https://orcid.org/0000-0003-4240-3265
Steiger, Katja https://orcid.org/0000-0002-7269-5433
Slotta-Huspenina, Julia
Weichert, Wilko
Zapata, Luis
Giota, Eleftheria
Lorenzen, Sylvie
Alberstmeier, Markus
Chain, Benny https://orcid.org/0000-0002-7417-3970
Friess, Helmut
Bengsch, Bertram https://orcid.org/0000-0003-2552-740X
Schmid, Roland M.
Siveke, Jens T. https://orcid.org/0000-0002-8772-4778
Quante, Michael https://orcid.org/0000-0002-8497-582X
Graham, Trevor A. https://orcid.org/0000-0001-9582-1597
-
Funding
Funding for this research was provided by:
Cancer Research UK
US NIH via the Cancer Systems Biology Consortium U54 scheme
Deutsche Krebshilfe
Bayerisches Zentrum für Krebsforschung
Deutsche Forschungsgemeinschaft
Bundesministerium für Bildung und Forschung
German Cancer Consortium
- License Information
-
More Information
Article History
Received: 26 March 2023
Accepted: 21 March 2025
First Online: 14 May 2025
Competing interests
: J.T.S. receives honoraria as a consultant or for continuing medical education presentations from AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Immunocore, iOMEDICO, MSD, Novartis, Roche/Genentech and Servier. His institution receives research funding from Abalos Therapeutics, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eisbach Bio and Roche/Genentech; he holds ownership in FAPI Holding. K. Steiger is named on a patent on a radiopharmaceutical compound and serves as advisory board member for TRIMT GmbH; not related to the current work. M.Q. receives honoraria as consultant or for continuing medical education presentations from AstraZeneca, Bayer, Bristol-Myers Squibb, MSD Sharp Dohme, Novartis, Roche and Servier. T.A.G., B.C. and A.M.B. are named as co-inventors on patent applications that describe a method for TCR sequencing (GB2305655.9) and T.A.G. is named on a patent application for a method to measure evolutionary dynamics in cancers using DNA methylation (GB2317139.0). T.A.G. has received an honorarium from Genentech and consultancy fees from DAiNA Therapeutics. The remaining authors declare no competing interests.
